Key Highlights

  • Shares rose 15.64% to USD 9.17 in the regular session on November 3, 2026.
  • The stock closed at USD 17.48 on October 27, 2026, before a drop of roughly 45% on October 28.
  • Cash and marketable securities were about USD 497 million at June 30, 2026.
  • Cash runway extends into the first half of 2029, according to the company.
  • A Phase 3 interim analysis is planned for mid-2027, with more than 200 trial sites active.

What Moved Bicara Therapeutics Today (up USD 1.24, 15.64%)

Bicara Therapeutics Inc. (NASDAQ:BCAX) rose 15.64% to USD 9.17 in regular trading on November 3, 2026, from a Monday, November 2 close of about USD 7.93. The screen showed Volume of 360.79K shares and a Market Capitalisation of about USD 606.81 million.

No company press release or regulatory filing dated between October 30 and November 3, 2026 was identified as the cause. The only scheduled item is the third quarter results release on November 9, 2026 at 8:30 a.m. ET. The gain looks like a bounce after a severe slide rather than a response to new information.

That slide began on October 28, 2026, when shares fell about 45% from USD 17.48 to near USD 9.68 on volume of about 12 million shares. Reports that day found no company news or filing explaining the decline. On October 29 one broker trimmed its target to USD 24 from USD 33 while keeping a positive rating, and on October 30 a downgrade to a negative rating with an USD 8 target coincided with an 8% drop.

Pipeline and Recent Updates

Bicara is a clinical-stage biotech developing bifunctional antibodies for solid tumours. Its lead candidate, ficerafusp alfa, targets EGFR on cancer cells while trapping TGF-beta, a signal that can dampen immune attack on tumours.

The pivotal programme is FORTIFI-HN01, a Phase 3 study in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. On its second quarter call the company said it was on track for substantial enrolment by the end of 2026, with more than 200 active sites, and planned an interim analysis in mid-2027 that could support an Accelerated Approval path.

Earlier data came at the ASCO meeting in May 2026, with three-year follow-up in about 90 patients across three dose cohorts. At the 1,500 mg weekly dose, roughly one in three patients was alive at three years, a figure drawn from a small cohort.

Financial Position and Risks

The company reported cash and marketable securities of about USD 497 million at the end of the second quarter and said this funds operations into the first half of 2029, covering the pivotal programme through a primary overall survival analysis, a planned regulatory filing and early commercial infrastructure. Second quarter EPS was a loss of USD 0.82 per share, and management expects operating expenses to keep rising through the rest of 2026.

Using the screen market capitalisation of USD 606.81 million, the Market Value is about 1.2 times the reported mid-year cash (calculated). The cash figure predates the third quarter.

The main risk is concentration: the valuation depends heavily on one late-stage asset in one indication. Insider selling disclosed under pre-arranged plans in August, a Leadership change and the lack of an identified cause for the October drop add to uncertainty.

What to Watch Next

The November 9, 2026 results should update cash, spending and trial timelines. Ryan Cohlhepp is due to become chief executive in January 2027, succeeding Claire Mazumdar, who will become vice chair. Data from two colorectal cancer cohorts of about 20 patients each are expected by the end of 2026.

Biotech shares can move sharply on little news, and this article is informational only.